Those results pave the way for novel potential preeclampsia therapies directed at restoring normal angiogenic balance in the maternal circulation akin to the previous lines demonstrating employment of VEGF agonists for ameliorating hypertension and proteinuria in murine models of preeclampsia (Bergmann et al., 2010; Li et al., 2007). This evidence concerns the gene VEGFA and preeclampsia.